Balchem Corporation
$ 180.29
0.37%
26 Feb - close price
- Market Cap 5,829,601,000 USD
- Current Price $ 180.29
- High / Low $ 181.35 / 177.37
- Stock P/E 39.39
- Book Value 39.22
- EPS 4.56
- Next Earning Report 2026-04-24
- Dividend Per Share $0.96
- Dividend Yield 0.54 %
- Next Dividend Date -
- ROA 0.08 %
- ROE 0.13 %
- 52 Week High 183.01
- 52 Week Low 138.32
About
Balchem Corporation develops, manufactures, and markets specialty ingredients and performance products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets in the United States and internationally. The company is headquartered in New Hampton, New York.
Analyst Target Price
$200.25
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-13 | 2025-10-21 | 2025-07-24 | 2025-05-01 | 2025-02-14 | 2024-10-25 | 2024-07-26 | 2024-05-03 | 2024-02-16 | 2023-10-27 | 2023-07-28 | 2023-04-28 |
| Reported EPS | 1.31 | 1.24 | 1.27 | 1.22 | 1.13 | 1.13 | 1.09 | 1.03 | 0.95 | 1.04 | 1.06 | 0.94 |
| Estimated EPS | 1.18 | 1.15 | 1.11 | 1.215 | 1.105 | 1.11 | 1.03 | 0.98 | 0.93 | 0.97 | 0.84 | 0.7 |
| Surprise | 0.13 | 0.09 | 0.16 | 0.005 | 0.025 | 0.02 | 0.06 | 0.05 | 0.02 | 0.07 | 0.22 | 0.24 |
| Surprise Percentage | 11.0169% | 7.8261% | 14.4144% | 0.4115% | 2.2624% | 1.8018% | 5.8252% | 5.102% | 2.1505% | 7.2165% | 26.1905% | 34.2857% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-24 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 1.24 |
| Currency | USD |
Previous Dividend Records
| Jan 2026 | Jan 2025 | Jan 2024 | Jan 2024 | Jan 2023 | Jan 1970 | Jan 2021 | Jan 1970 | Jan 1970 | Jan 1970 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-01-20 | 2025-01-17 | 2024-01-16 | 2024-01-19 | 2023-01-20 | None | 2021-01-22 | None | None | None |
| Amount | $0.96 | $0.87 | $0.3984 | $0.79 | $0.71 | $0.64 | $0.58 | $0.52 | $0.47 | $0.42 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BCPC
2026-02-26 02:53:12
Balchem (BCPC) recently released strong Q4 and full-year 2025 results, with share price gains of 7.78% over 30 days and 16.62% year-to-date. Despite its current P/E ratio of 37.1x being higher than the industry average, analysts have a fair value estimate of $191, suggesting the stock is 6% undervalued. Key factors supporting future growth include a new microencapsulation facility and a strong clinical research pipeline.
2026-02-24 17:52:06
Balchem Corp., a small-cap FMCG player, has undergone a valuation adjustment, showing strong financial metrics like a P/E ratio of 34, a 49.00% dividend yield, and competitive returns on capital and equity. These figures indicate a stronger market position compared to peers like The J. M. Smucker Co. and Conagra Brands, Inc., which have significantly lower P/E ratios. This highlights Balchem's competitive advantage within the FMCG industry.
2026-02-24 11:52:06
Balchem Corporation, a specialty ingredient manufacturer, announced its participation in the JP Morgan Consumer Ingredients Forum on March 10, 2026. Key executives, including Chairman, President, and CEO Ted Harris, CFO Martin Bengtsson, and Senior Director of Investor Relations Allison Baurichter, will represent the company. Balchem focuses on health and nutrition markets with segments in Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products.
2026-02-21 13:11:49
Balchem Corporation reported record fourth quarter and full-year 2025 financial results, with consolidated sales reaching $1.037 billion for the first time, an 8.8% increase from the prior year. The company achieved strong growth across all three segments—Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products—and delivered its 26th consecutive quarter of year-over-year adjusted EBITDA growth. Balchem also highlighted strategic investments in marketing partnerships, clinical research, and sustainability goals, while maintaining a focus on capital deployment through organic growth, M&A, debt reduction, and consistent dividend increases.
2026-02-21 01:50:21
Balchem Corporation reported record financial results for Q4 and full fiscal year 2025, with net sales rising 9.8% year-over-year and full-year revenue surpassing $1 billion. GAAP net earnings increased by 16.8% for the quarter and 20.5% for the full year, driven by strong performance across its Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products segments. The company also announced a 10% increase in its annual dividend, expressing optimism for continued growth in 2026.
2026-02-20 18:13:09
Balchem Corporation reported record financial results for Q4 and full-year 2025, exceeding $1 billion in annual sales driven by strong performance across all three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. The company discussed strategic initiatives including international expansion, significant investments in clinical research, and marketing partnerships, while highlighting sustainability achievements and a strong financial position with record free cash flow and a low leverage ratio. Management also addressed the Supreme Court ruling on tariffs and detailed their capital allocation priorities focused on organic growth, M&A, and shareholder returns.
